Naturally-acquired immunity in Syrian Golden Hamsters provides protection from re-exposure to emerging heterosubtypic SARS-CoV-2 variants B.1.1.7 and B.1.351
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The ability of acquired immune responses against SARS-CoV-2 to protect after subsequent exposure to emerging variants of concern (VOC) such as B1.1.7 and B1.351 is currently of high significance. Here, we use a hamster model of COVID-19 to show that prior infection with a strain representative of the original circulating lineage B of SARS-CoV-2 induces protection from clinical signs upon subsequent challenge with either B1.1.7 or B1.351 viruses, which recently emerged in the UK and South Africa, respectively. The results indicate that these emergent VOC may be unlikely to cause disease in individuals that are already immune due to prior infection, and this has positive implications for overall levels of infection and COVID-19 disease.
Article activity feed
-
SciScore for 10.1101/2021.03.10.434447: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Experimental animals: Animal work was approved by the local University of Liverpool Animal Welfare and Ethical Review Body and performed under UK Home Office Project Licence PP4715265. Randomization Virus infection: Animals were randomly assigned into multiple cohorts. Blinding not detected. Power Analysis not detected. Sex as a biological variable Male golden Syrian hamsters were purchased from Janvier Labs (France). Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Virus isolates: A PANGO lineage B strain of SARS-CoV-2 (hCoV-2/human/Liverpool/REMRQ0001/2020), which was cultured from a nasopharyngeal swab … SciScore for 10.1101/2021.03.10.434447: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Experimental animals: Animal work was approved by the local University of Liverpool Animal Welfare and Ethical Review Body and performed under UK Home Office Project Licence PP4715265. Randomization Virus infection: Animals were randomly assigned into multiple cohorts. Blinding not detected. Power Analysis not detected. Sex as a biological variable Male golden Syrian hamsters were purchased from Janvier Labs (France). Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Virus isolates: A PANGO lineage B strain of SARS-CoV-2 (hCoV-2/human/Liverpool/REMRQ0001/2020), which was cultured from a nasopharyngeal swab collected from a patient in Liverpool in March 2020, was passaged in Vero E6 cells and used at P4 16. Vero E6suggested: RRID:CVCL_XD71)V2.HV001) isolate 18 was received at P3 from the Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, in Oxford in January 2021, passaged in VeroE6/TMPRSS2 cells (NIBSC reference 100978), used here at P4. VeroE6/TMPRSS2suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:There are caveats with the presented data. The study was conducted in a hamster model where responses will be similar but likely not identical to humans. Also, the time from exposure to re-challenge is relatively short at only 3 weeks. However, these data do provide a very good, direct indication that exposure to or vaccination against SARS-CoV-2 will protect against exposure to the variants that emerged in late 2020 in the UK and South Africa. Our data suggest that protection will be better than suggested by in vitro neutralising antibody studies and that a degree of herd immunity will be achievable. Ongoing reconnaissance as SARS-CoV-2 continues to evolve is warranted.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
